NASDAQ$VTYX

Ventyx Biosciences Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Ventyx Biosciences reported financial results for the third quarter of 2023 and highlighted recent corporate progress.

Ventyx Biosciences reported a net loss of $54.0 million for the third quarter of 2023, with cash, cash equivalents, and marketable securities totaling $300.8 million as of September 30, 2023. The company is focused on advancing its pipeline of oral therapies and expects to provide clinical updates in the first quarter of 2024.

  • Cash, cash equivalents and marketable securities were $300.8 million as of September 30, 2023.
  • Research and Development expenses were $49.8 million for the quarter ended September 30, 2023.
  • General and Administrative expenses were $8.2 million for the quarter ended September 30, 2023.
  • Net loss was $54.0 million for the quarter ended September 30, 2023.

Headline financials

Total Revenue

$0.00

No prior period
EPS (adj)

-$0.92

Previous: -$0.59-55.9%
Capital Expenditures

-$48K

Previous: $97K-149.5%
Free Cash Flow

-$34.7M

Previous: -$24.1M-44.1%
Net Income

-$54M

Previous: -$29.5M-83.0%
Operating Income

-$58M

Previous: -$31.4M-84.4%
Gross Profit

-$265K

No prior period
Cash & Equivalents

$301M

Previous: $263M+14.3%
Total Assets

$322M

Previous: $420M-23.5%
R&D Expense

$49.8M

No prior period
Stock-Based Comp

$8.01M

Previous: $4.17M+92.2%

Revenue & EPS history

Ventyx Biosciences · Revenue · Quarterly

$0

Q3 2023

Forward guidance

Ventyx anticipates providing updates across its clinical-stage portfolio in the first quarter of 2024.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 8 quarterly earnings reports

Historical avg

+4.2%

Avg return

Earnings day

+7.1%

Avg return

5 days after

+13.8%

Avg return

30 days after

56%

10 / 18 earnings

Positive

+34.4%

Q2 2022

Best reaction

-11.9%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025-5.7%+2.5%-6.0%
Q2 2025+18.4%+20.5%+6.8%
Q1 2025+7.0%+1.8%+113.2%
Q4 2024+9.0%+4.2%-16.1%
Q3 2024-5.6%-10.0%+34.2%
Q2 2024+5.6%-0.5%+10.9%
Q1 2024-7.9%-6.3%-26.4%
Q4 2023+32.6%+45.0%-6.5%
Q3 2023-11.9%
Q2 2023+1.9%
Q1 2023-11.6%
Q4 2022-8.3%
Q3 2022-9.1%
Q2 2022+34.4%
Q1 2022+10.6%
Q2 2021+9.3%
Q4 2021+9.3%
Q3 2021-1.7%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro